Sermorelin: A Growth Hormone-Releasing Hormone Analog for Therapeutic Use

Growth Hormone (GH) deficiency can lead to various metabolic and physiological impairments, including reduced muscle mass, increased adiposity, and decreased bone density. While recombinant human GH (rhGH) is a treatment option, it can suppress endogenous GH production. Sermorelin is a synthetic peptide that mimics Growth Hormone-Releasing Hormone (GHRH), stimulating the pituitary gland to naturally secrete GH. Understanding the precise mechanisms and optimal therapeutic applications of Sermorelin, particularly its long-term efficacy and safety profile, remains an active area of research.

Studies on Sermorelin consistently demonstrate its ability to stimulate endogenous GH release. For example, in GH-deficient adults, Sermorelin treatment has been shown to increase peak GH levels by 2.5-fold compared to placebo (p<0.001). This elevation in GH typically translates to a significant increase in Insulin-like Growth Factor 1 (IGF-1), with levels rising by an average of 43% after 3 months of therapy. Furthermore, Sermorelin has been observed to improve sleep quality and enhance exercise capacity, with 70% of patients reporting subjective improvements in well-being. The most significant finding across various studies is that Sermorelin therapy can lead to a 15-20% reduction in body fat and a 5-10% increase in lean muscle mass over 6-12 months in individuals with GH insufficiency, without the direct exogenous GH administration.